---

---

tags : Covid-19    symbols : GLAXF   

save search

---

Global mRNA Vaccine Market Research Report 2023-2028: COVID-19 Success Opens New Avenues with with 444 Ongoing Clinical Studies Worldwide
Published: 2023-11-08 (Crawled : 03:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 17.03% | O: 1.91% H: 0.0% C: 0.0%
VERV | $6.66 -1.19% -1.2% 1.2M |

Professional, Scientific, and T...

| -63.96% | O: 0.37% H: 0.64% C: -10.76%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 13.21% | O: 0.46% H: 0.46% C: -0.23%
MRNA S | $102.015 -1.38% -1.4% 1.7M |

Health Technology

| 40.43% | O: -0.01% H: 0.03% C: -3.14%
CVAC | News | $2.44 -5.06% -5.33% 710K |

Health Technology

| -55.72% | O: 0.91% H: 1.08% C: -1.44%
BNTX | $86.19 -0.24% -0.24% 580K |

Health Technology

| -15.82% | O: 0.13% H: 0.08% C: -2.81%
ARCT 4 | $26.31 -4.81% -5.06% 610K |

Health Technology

| 34.35% | O: -0.36% H: 0.79% C: -0.61%
covid-19 success report vaccine mrna worldwide ongoing research global market

---

COVID-19 Challenges Drive the Need for Resilient Supply Chains and Digital Healthcare in the Anti-Epileptic Drugs Market, Shaping the Post-Pandemic Landscape
Published: 2023-11-06 (Crawled : 19:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 17.51% | O: 0.41% H: 0.0% C: 0.0%
VTRS | $11.11 0.09% 0.09% 3.5M |

Health Technology

| 20.74% | O: 0.11% H: 0.33% C: -0.98%
TEVA | $12.78 -3.03% -0.24% 9M |

Health Technology

| 45.64% | O: 0.22% H: 1.49% C: -0.33%
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -4.08% | O: 0.44% H: 0.22% C: 0.07%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -0.4% | O: 0.24% H: 0.18% C: 0.16%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -4.43% | O: 0.18% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 13.83% | O: 0.55% H: 0.3% C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M |

Health Technology

| 11.32% | O: -0.42% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -0.36% | O: -1.32% H: 0.0% C: 0.0%
covid-19

---

CureVac meldet Fortschritte in klinischen Phase-2-Entwicklungsprogrammen für COVID-19 und die saisonale Grippe in Zusammenarbeit mit GSK
Published: 2023-11-01 (Crawled : 13:00) - curevac.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 12.22% | O: -1.62% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 10.92% | O: -4.06% H: 1.9% C: 0.96%
CVAC | News | $2.44 -5.06% -5.33% 710K |

Health Technology

| -53.96% | O: 0.19% H: 3.95% C: -1.32%
covid-19 phase 2

---

CureVac veröffentlicht positive Daten bei älteren Erwachsenen aus COVID-19- und Grippe-mRNA-Impfstoffentwicklungsprogrammen
Published: 2023-01-30 (Crawled : 12:20) - curevac.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 13.67% | O: -2.59% H: 3.12% C: 1.79%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 12.18% | O: 0.74% H: 0.2% C: -1.24%
CVAC | News | $2.44 -5.06% -5.33% 710K |

Health Technology

| -78.58% | O: 5.36% H: 4.0% C: -3.5%
covid-19 positive

---

CureVac gibt positive Daten aus gemeinsamen COVID-19- und Grippe-mRNA-Impfstoffentwicklungsprogrammen bekannt
Published: 2023-01-06 (Crawled : 12:20) - curevac.com
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 14.85% | O: -0.44% H: 1.85% C: 1.72%
CVAC | News | $2.44 -5.06% -5.33% 710K |

Health Technology

| -61.76% | O: 12.7% H: 15.44% C: 14.88%
covid-19 positive

---

Global Pharmaceutical Packaging Market Report 2022-2027: Supply Chain Analysis, Technologies, Regulations, Future Trends, Impacts of COVID-19
Published: 2023-01-05 (Crawled : 12:20) - prnewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 15.03% | O: -1.77% H: 0.75% C: 0.75%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -19.53% | O: -0.62% H: 0.54% C: -0.12%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 13.05% | O: -1.28% H: 0.35% C: -0.29%
AMCR | News | $8.9 0.79% 0.0% 5.8M |

Process Industries

| -26.52% | O: -0.83% H: 0.59% C: -0.08%
covid-19 global report market

---

Gastrointestinal Drugs Market Research Report by Drug Category, Route of Administration, Disease Type, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-23 (Crawled : 15:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 12.85% | O: -3.13% H: 0.0% C: -0.23%
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -14.72% | O: 0.13% H: 0.71% C: 0.65%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 12.15% | O: -0.14% H: 0.28% C: -0.11%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -5.35% | O: -0.23% H: 0.0% C: 0.0%
covid-19 drug research global disease report impact gastrointestinal market

---

Non-steroidal Anti-inflammatory Drugs Market Research Report by Disease Indication, Drugs, Route of Administration, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-07 (Crawled : 16:00) - prnewswire.com
RBGPF | $52.0 6.46% 34K |

Consumer Non-Durables

| -26.52% | O: 0.06% H: 3.15% C: 0.15%
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 7.16% | O: 0.74% H: 0.0% C: -6.74%
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| -4.51% | O: 1.62% H: 0.0% C: -4.28%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| -1.06% | O: -0.56% H: 0.61% C: 0.01%
RBGLY | $10.29 -2.05% 1.4M |

Manufacturing

| -29.45% | O: 0.51% H: 0.48% C: -0.14%
VTRS | $11.11 0.09% 0.09% 3.5M |

Health Technology

| 1.74% | O: 0.0% H: 0.55% C: -0.27%
ZTS | News | $153.11 1.05% 0.48% 4.8M |

Health Technology

| -1.08% | O: -0.06% H: 0.54% C: -1.77%
PRGO | $29.94 -0.33% 0.0% 970K |

Health Technology

| -5.33% | O: -0.09% H: 0.47% C: -0.28%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 4.43% | O: -0.98% H: 0.24% C: -1.78%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 103.71% | O: 0.21% H: 1.6% C: 0.72%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| 0.86% | O: 5.18% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| -0.43% | O: 0.45% H: 0.64% C: -0.03%
covid-19 research global disease report impact distribution market

---

Cellular Immunotherapy Market Research Report by Type, Indication, Technology Type, End Use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-11-10 (Crawled : 17:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 29.9% | O: -0.06% H: 0.0% C: 0.0%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 12.29% | O: 6.22% H: 3.13% C: -0.56%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| 12.19% | O: 2.81% H: 0.43% C: -0.2%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -16.77% | O: 0.18% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 22.15% | O: 2.59% H: 0.72% C: 0.63%
BMY | $48.3 0.96% -0.1% 11M |

Health Technology

| -39.46% | O: 1.22% H: 0.01% C: -1.7%
IOVA M | $11.72 -0.68% -0.68% 3.6M |

Health Technology

| 50.51% | O: 6.12% H: 4.99% C: 4.21%
INO 3 d | $10.22 -7.68% -8.32% 400K |

Health Technology

| 367.89% | O: 5.5% H: 4.35% C: 3.48%
GILD | News | $66.16 -1.15% -1.16% 6.4M |

Health Technology

| -18.73% | O: 1.43% H: 0.36% C: -1.08%
ATRA | $0.6917 -3.25% -3.35% 830K |

Health Technology

| -82.43% | O: 2.58% H: 23.12% C: 20.85%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 11.82% | O: 7.08% H: 0.84% C: -0.43%
ADAP | $0.8984 -8.98% -9.86% 3.3M |

Health Technology

| -50.95% | O: 0.0% H: 7.14% C: 5.71%
covid-19 research global immunotherapy report impact technology market

---

CureVac beginnt mit klinischer Phase 1-Studie für modifizierten COVID-19-Impfstoffkandidaten gegen Omikron-Variante
Published: 2022-08-18 (Crawled : 12:00) - curevac.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 22.0% | O: -3.07% H: 9.03% C: 4.86%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 14.12% | O: -0.32% H: 0.03% C: -0.98%
CVAC | News | $2.44 -5.06% -5.33% 710K |

Health Technology

| -81.49% | O: -0.61% H: 1.64% C: -4.58%
covid-19 phase 1

---

The Gynecology Drugs Market Is To Reach $26 Bn As It Recovers From The COVID-19 Impact
Published: 2022-05-04 (Crawled : 15:20) - prnewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| -27.21% | O: -1.58% H: 0.0% C: 0.0%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 4.02% | O: 3.26% H: 0.0% C: -3.77%
PKX | News | $70.1 3.24% 0.0% 110K |

Non-Energy Minerals

| 23.3% | O: 0.38% H: 2.4% C: 2.4%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| -12.23% | O: -0.2% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 1.63% | O: -0.79% H: 0.0% C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| 13.81% | O: -0.09% H: 1.95% C: 1.52%
covid-19 market drug

---

GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
Published: 2022-01-13 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| -11.65% | O: 0.0% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| -12.62% | O: 0.29% H: 0.0% C: 0.0%
XNCR | $18.98 -0.47% -0.47% 470K |

Health Technology

| -47.68% | O: 0.38% H: 1.12% C: -1.31%
VIR | $7.96 -3.52% -3.64% 880K |

Health Technology

| -79.38% | O: 1.05% H: 1.98% C: -6.88%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -11.46% | O: -0.74% H: 0.0% C: 0.0%
covid-19 treatment fda application covid authorization merge emergency use authorization

---

Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
Published: 2021-12-17 (Crawled : 13:30) - globenewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| -4.72% | O: 2.36% H: 0.46% C: 0.46%
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| -3.77% | O: -0.48% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| -8.4% | O: 0.86% H: 0.0% C: 0.0%
XNCR | $18.98 -0.47% -0.47% 470K |

Health Technology

| -47.87% | O: -0.45% H: 0.0% C: 0.0%
VIR | $7.96 -3.52% -3.64% 880K |

Health Technology

| -85.14% | O: -4.59% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -7.59% | O: 0.22% H: 0.0% C: 0.0%
covid-19 treatment europe granted covid authorization grant

---

GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
Published: 2021-11-17 (Crawled : 12:00) - globenewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| -2.23% | O: 1.43% H: 2.31% C: 2.27%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| -6.54% | O: -0.28% H: 0.0% C: 0.0%
VIR | $7.96 -3.52% -3.64% 880K |

Health Technology

| -74.73% | O: 9.97% H: 4.0% C: -6.28%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -11.13% | O: -0.06% H: 0.0% C: 0.0%
covid treatment biotech technology iot covid-19

---

CureVac verlagert Fokus der COVID-19-Impfstoffentwicklung auf mRNA-Technologie der zweiten Generation
Published: 2021-10-12 (Crawled : 12:00) - curevac.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 3.59% | O: 3.38% H: 0.0% C: -5.75%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 3.56% | O: 2.51% H: 0.15% C: -1.43%
CVAC | News | $2.44 -5.06% -5.33% 710K |

Health Technology

| -94.35% | O: -13.04% H: 13.08% C: 9.7%
covid covid-19

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---